doqujamup.wordpress.com
Bayhill could receive the $325 million beyond the upfronrt payment and investment through regulatory and sales Bayhill also could receive royalties on annual net sales and has an optionh on future development and marketing of the drug in North Bayhill will be responsible for completing the ongoingyPhase I/II trial of the South San Francisco-based Genentech, a subsidiar of Swiss drug maker , will lead all future development, manufacturing and commercialization.
As part of the Genentech will reimburse Bayhill the remaining costs of the current triaol and will fund all future Bayhill chief executive officer and presidenyt Mark Schwartz said the deal accelerates developmentyof BHT-3021 while allowinb the companies to continue to develop additional products. The drug work by turning off an errant autoimmunew response attackingthe pancreas. That could preserve the functionas of the pancreas andimprove long-term healtu in type 1 diabetes patients, Bayhill
No comments:
Post a Comment